Cellectis Reports Q1 2025 Financial Results and Strategic Progress

Cellectis S.A. ( (CLLS) ) has released its Q1 earnings. Here is a breakdown of the information Cellectis S.A. presented to its investors.

Cellectis S.A. is a clinical-stage biotechnology company that leverages its pioneering gene-editing platform to develop innovative cell and gene therapies, focusing on allogeneic CAR T immunotherapies for oncology and other therapeutic areas.

In its first-quarter 2025 earnings report, Cellectis highlighted significant progress in its clinical and research programs, including ongoing Phase 1 studies of its UCART22 and UCART20x22 therapies, as well as its strategic partnership with AstraZeneca. The company also showcased advancements in non-viral gene editing and base editing technologies.

Financially, Cellectis reported a cash position of $246 million, providing a runway into the second half of 2027. Revenues and other income for the quarter increased to $12 million, up from $6.5 million in the same period last year, driven by progress in its collaboration with AstraZeneca. However, the company faced a net loss of $18.1 million, attributed to a significant decrease in net financial gain compared to the previous year.

Cellectis continues to focus on its core programs, with upcoming data presentations and strategic developments expected later in 2025. The company remains committed to advancing its pipeline and leveraging its in-house manufacturing capabilities to support future growth.

Looking ahead, Cellectis management maintains a positive outlook, emphasizing the potential of its gene-editing technologies and strategic collaborations to drive innovation and therapeutic advancements in the biotechnology sector.